Actemra data presented at ACR Annual meeting on rapid response and long-term efficacy in people with rheumatoid arthritis.

Genentech Inc announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving Actemra (tocilizumab) experienced a rapid, measured response as early as one week after beginning Actemra, and improvement in disease activity within four weeks. Additionally, combined data from three other Phase III studies showed that RA patients who received Actemra had sustained improvements in signs and symptoms over nearly two years. These data will be presented at the 2010 American College of Rheumatology (ACR) Annual Scientific Meeting in Atlanta, 7-11 Nov 2010. Across the pooled studies, the overall safety of Actemra was consistent with earlier data and …